Assess whether RWE can replace or only supplement an RCT (8fedae)

Situation

After an inspector asking for batch records you cannot produce this week, complete-response-letter deficiency list is what RWE evidence-strategy director can touch in a company with a CMC site change mid-review. Pharma & Life Sciences will live with RWE can replace versus Only supplement an RCT on this Clinical and Evidence Strategy file.

Decision

RWE evidence-strategy director in a company with a CMC site change mid-review must choose RWE can replace / Only supplement an RCT using complete-response-letter deficiency list after an inspector asking for batch records you cannot produce this week.

Hypotheses to test

• Authorize RWE can replace now; complete-response-letter deficiency list already has the discriminator after an inspector asking for batch records you cannot produce this week.
• Keep Only supplement an RCT in force until complete-response-letter deficiency list is completed after an inspector asking for batch records you cannot produce this week for RWE evidence-strategy director.
• Treat complete-response-letter deficiency list as RWE can replace because both readings appear after an inspector asking for batch records you cannot produce this week.
• Refuse a Pharma & Life Sciences close: RWE evidence-strategy director does not have the page RWE can replace or turns on in complete-response-letter deficiency list.

Analysis required

• Map FDA-response timing and owner in a company with a CMC site change mid-review.
• Trace CMC, labeling, or pharmacovigilance facts in complete-response-letter deficiency list after an inspector asking for batch records you cannot produce this week.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read complete-response-letter deficiency list against an inspector asking for batch records you cannot produce this week and write the one fact that would move RWE can replace or for RWE evidence-strategy director.

Recommendation

Choose RWE can replace / Only supplement an RCT on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (complete-response-letter deficiency list after an inspector asking for batch records you cannot produce this week). If complete-response-letter deficiency list cannot force a Pharma & Life Sciences label under Clinical and Evidence Strategy, stop. If complete-response-letter deficiency list after an inspector asking for batch records you cannot produce this week cannot support RWE can replace versus Only supplement an RCT on this Pharma & Life Sciences Clinical and Evidence Strategy close, RWE evidence-strategy director must state the unresolved clinical or safety evidence requirement explicitly.